GlobeNewswire Inc | Aug 5, 2020 07:00AM EDT

August 05, 2020

CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress, taking place on September 18-22, 2020.

Mini Oral Presentations:

Clinical Benefit in Biomarker-Positive Patients (pts) with LocallyTitle: Advanced or Metastatic Solid Tumors Treated with the PARP1/2 Inhibitor Pamiparib in Combination with Low-Dose (LD) Temozolomide (TMZ)Mini Oral 530MO#:Session Developmental TherapeuticsTitle:Presenter: Agostina Stradella, M.D. Catalan Institute of Oncology, Spain

Title: BGB-A333, an Anti-PD-L1 Monoclonal Antibody, in Combination with Tislelizumab in Patients with Urothelial CarcinomaMini Oral 535MO#:Session Developmental TherapeuticsTitle:Presenter: Juan Martin-Liberal, M.D., Ph.D., Catalan Institute of Oncology, Spain

Poster Presentations:

Title: Phase 2 Study of Pamiparib in Chinese Patients (pts) with Advanced Ovarian Cancer (aOC)Poster #: 820PSession Poster DisplayTitle:Lead Xiaohua Wu, M.D., Ph.D., Fudan University Shanghai Cancer Center,Author: China

Title: Safety and Efficacy of Long-term Exposure (LTE) to Tislelizumab in Chinese Patients with Advanced Solid TumorsPoster #: 522PSession Poster DisplayTitle:Lead Lin Shen, M.D., Ph.D., Peking University Cancer Hospital & InstituteAuthor: , China

Title: Tislelizumab + Chemotherapy vs Chemotherapy Alone as First-line Treatment for Locally Advanced/Metastatic Nonsquamous NSCLCPoster #: 1263PSession Poster DisplayTitle:Lead Shun Lu, M.D., Shanghai Chest Hospital, ChinaAuthor:

Updated Analysis of Tislelizumab Plus Chemotherapy vs ChemotherapyTitle: Alone as First-line Treatment of Advanced Squamous Non-Small Cell Lung Cancer (SQ NSCLC)Poster 1264P#:Session Poster DisplayTitle:Lead Jie Wang, M.D., Ph.D., National Cancer Center/Cancer Hospital, ChinaAuthor:

Investigation of PD-L1 Expression and Tislelizumab Efficacy inTitle: Gastroesophageal Adenocarcinoma Using a Novel Tumor and Immune Cell Score with VENTANA PD-L1 (SP263) Assay and Combined Positive Score (CPS)Poster 154P#:Session Poster DisplayTitle:Lead Yee Chao, Ph.D., Taipei Veterans General Hospital, TaiwanAuthor:

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,100+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Srl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

Investor Contact Media ContactCraig West Liza Heapes or Vivian Ni+1 857-302-5189 +1 857-302-5663 or +1 857-302-7596ir@beigene.com media@beigene.com